New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
04:55 EDTMRGE, MRGE, KND, KND, IMMU, IMMU, COO, COO, CVS, CVS, ARNA, ARNA, GMED, GMED, ISIS, ISIS, Q, Q, STML, STML, BDSI, BDSI, DEPO, DEPOWells Fargo to hold a conference
2014 Healthcare Conference to be held in Boston on June 17-18.
News For MRGE;BDSI;STML;Q;ISIS;GMED;ARNA;CVS;COO;IMMU;KND;DEPO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 14, 2015
17:04 EDTKNDKindred Healthcare expands operations into three new states
Kindred Healthcare announced that Kindred House Calls, the company’s home-based primary care business, has expanded into three additional states. Kindred recently acquired House Call Doctors of Austin, Texas, whose CEO Julia Jung has joined Kindred’s Managed Care Group. Terms of the transaction were not disclosed. In March, Kindred acquired Physician House Calls in Denver, Colorado. Terms of the transaction were not disclosed. Kindred House Calls is also integrating two primary care practices that were part of Gentiva Health Services, acquired in February. The Gentiva practices are located in Austin, Texas, and Spokane, Washington.
16:11 EDTBDSIEndo, BioDelivery announces Phase 3 data for buprenorphine
Subscribe for More Information
07:35 EDTQQuintiles 11.9M share Spot Secondary priced at $65.00
Subscribe for More Information
May 13, 2015
16:42 EDTQQuintiles announces offering of 11.86M shares of common stock for holders
Subscribe for More Information
11:47 EDTCVSCVS Health says to pay $22M in settlement with DEA, USAO
CVS Health said in a regulatory filing that it has entered into an agreement with the U.S. Attorney’s Office for the Middle District of Florida and the U.S. Drug Enforcement Administration to resolve previously-disclosed allegations relating to the dispensing of certain controlled substances in Florida. CVS Health agreed to pay $22M and the settlement resolves all civil matters between the Company and the DEA in the state of Florida. This payment amount has been fully accrued for in prior fiscal periods.
08:43 EDTDEPODepomed weakness overdone, says Roth Capital
Subscribe for More Information
May 12, 2015
12:44 EDTDEPODepomed selloff an overreaction, says Roth Capital
Subscribe for More Information
12:24 EDTDEPODepomed upgraded to Buy from Neutral at Janney Capital
Subscribe for More Information
09:20 EDTDEPOOn The Fly: Pre-market Movers
Subscribe for More Information
08:36 EDTIMMUImmunomedics extends U.S. patent protection for sacituzumab govitecan
Subscribe for More Information
07:00 EDTBDSIBioDelivery Sciences price target lowered to $12 from $17 at Cantor
Subscribe for More Information
May 11, 2015
19:15 EDTARNAOn The Fly: After Hours Movers
Subscribe for More Information
16:41 EDTARNAArena Pharmaceuticals reports Q1 EPS (10c), consensus (14c)
Subscribe for More Information
16:35 EDTDEPODepomed sees 2015 sales $310M-$335M, consensus $305M
Subscribe for More Information
16:34 EDTDEPODepomed reports Q1 adjusted EPS (13c), consensus 1c
Subscribe for More Information
16:22 EDTARNAArena Pharmaceuticals enters collaboration with Roivant Sciences
Arena Pharmaceuticals announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Roivant exclusive worldwide rights to develop and commercialize nelotanserin. Nelotanserin has been studied to date in multiple clinical trials involving over 900 subjects. Roivant intends to initiate additional Phase 2 clinical trials for the treatment of behavioral and neuropsychiatric disturbances, including psychoses, in patients with dementia and other neurological diseases. In addition, Roivant may pursue the development of nelotanserin for other neuropsychiatric disorders. Roivant will be responsible for funding the development and commercialization of nelotanserin. Under the agreement, Arena will manufacture clinical supply and commercial product to sell to Roivant. Arena will receive a $4.0M upfront payment and is eligible to receive $41.5M in regulatory and development milestone payments. Arena is also eligible to receive 15% of net sales of nelotanserin in exchange for the manufacture and supply of finished commercial drug product, and up to a total of $60.0M in one-time purchase price adjustment payments tied to certain commercial sales milestones.
08:23 EDTSTMLStemline reports Q1 EPS (46c), consensus (45c)
Subscribe for More Information
07:40 EDTCVSFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertex’s Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasn’t announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
07:16 EDTBDSIBioDelivery Sciences reports 11K prescriptions dispensed for Bunavail during Q1
Subscribe for More Information
07:16 EDTBDSIBioDelivery Sciences reports Q1 EPS (16c), consensus (19c)
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use